MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, APGE had -$10,534K decrease in cash & cash equivalents over the period. -$232,597K in free cash flow.

Cash Flow Overview

Change in Cash
-$10,534K
Free Cash flow
-$232,597K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Proceeds from issuance of common...
    • Proceeds from issuance of common...
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Net loss
    • Other assets
    • Others

Cash Flow
2025-12-31
Net loss
-255,843
Depreciation expense
1,418
Equity-based compensation expense
46,277
Amortization of discounts on marketable securities
7,501
Non-cash lease expense
3,677
Prepaid expenses and other current assets
2,106
Other assets
8,467
Accounts payable
150
Operating lease liability
-3,981
Accrued expenses
-1,074
Net cash used in operating activities
-227,450
Purchases of marketable securities
642,300
Maturities of marketable securities
467,873
Purchases of property and equipment
5,147
Net cash used in investing activities
-179,574
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs
324,052
Proceeds from issuance of common stock under atm equity offering program, net of issuance costs
65,582
Proceeds from exercise of options and employee stock purchase plan purchases
6,856
Net cash provided by financing activities
396,490
(decrease) increase in cash, cash equivalents and restricted cash
-10,534
Cash, cash equivalents and restricted cash, beginning of period
142,083
Cash, cash equivalents and restricted cash, end of period
131,549
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock and...$324,052K Proceeds from issuance ofcommon stock under atm...$65,582K Proceeds from exercise ofoptions and employee...$6,856K Net cash provided byfinancing activities$396,490K (decrease) increase incash, cash...-$10,534K Canceled cashflow$396,490K Equity-based compensationexpense$46,277K Non-cash lease expense$3,677K Depreciation expense$1,418K Accounts payable$150K Maturities of marketablesecurities$467,873K Net cash used inoperating activities-$227,450K Canceled cashflow$51,522K Net cash used ininvesting activities-$179,574K Canceled cashflow$467,873K Net loss-$255,843K Other assets$8,467K Amortization of discounts onmarketable securities$7,501K Operating lease liability-$3,981K Prepaid expenses andother current assets$2,106K Accrued expenses-$1,074K Purchases of marketablesecurities$642,300K Purchases of property andequipment$5,147K

Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics, Inc. (APGE)